Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Gutman

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Blood|August 6, 2010
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord bloodClaudio G Brunstein, Jonathan A Gutman, Daniel J Weisdorf, et al.
Bone Marrow Transplantation|October 31, 2019
Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantationPrashant Sharma, Neel Gakhar, Jennifer MacDonald, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 1, 2019
Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy PopulationTaylor Morrisette, Amanda G Van Matre, Matthew A Miller, et al.
Haematologica|December 18, 2023
Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidineAmanda C Winters, Mohd Minhajuddin, Brett M Stevens, et al.
Leukemia & Lymphoma|September 22, 2015
Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution seriesBrett Stevens, Julia Maxson, Jeffrey Tyner, et al.
Blood Advances|October 5, 2021
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemiaEvan M Cherry, Diana Abbott, Maria Amaya, et al.
Transplantation and Cellular Therapy|August 18, 2024
Outcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective AnalysisAndrew Kent, Kellen B Gil, Michael K Jones, et al.
Stem Cells and Cloning : Advances and Applications|August 8, 2015
Progress toward curing HIV infection with hematopoietic cell transplantationLawrence D Petz, John C Burnett, Haitang Li, et al.
Leukemia Research|April 23, 2019
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysisBrett Stevens, Amanda Winters, Jonathan A Gutman, et al.
Nature Medicine|November 14, 2018
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemiaDaniel A Pollyea, Brett M Stevens, Courtney L Jones, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Blood|August 6, 2010
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord bloodClaudio G Brunstein, Jonathan A Gutman, Daniel J Weisdorf, et al.
Bone Marrow Transplantation|October 31, 2019
Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantationPrashant Sharma, Neel Gakhar, Jennifer MacDonald, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 1, 2019
Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy PopulationTaylor Morrisette, Amanda G Van Matre, Matthew A Miller, et al.
Haematologica|December 18, 2023
Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidineAmanda C Winters, Mohd Minhajuddin, Brett M Stevens, et al.
Leukemia & Lymphoma|September 22, 2015
Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution seriesBrett Stevens, Julia Maxson, Jeffrey Tyner, et al.
Blood Advances|October 5, 2021
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemiaEvan M Cherry, Diana Abbott, Maria Amaya, et al.
Transplantation and Cellular Therapy|August 18, 2024
Outcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective AnalysisAndrew Kent, Kellen B Gil, Michael K Jones, et al.
Stem Cells and Cloning : Advances and Applications|August 8, 2015
Progress toward curing HIV infection with hematopoietic cell transplantationLawrence D Petz, John C Burnett, Haitang Li, et al.
Leukemia Research|April 23, 2019
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysisBrett Stevens, Amanda Winters, Jonathan A Gutman, et al.
Nature Medicine|November 14, 2018
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemiaDaniel A Pollyea, Brett M Stevens, Courtney L Jones, et al.
Pageof 6